Long-term efficacy and safety adalimumab in children with juvenile rheumatoid arthritis (JRA): converting from body-surface-area dosing to weight-based fixed dosing in the open-label extension (OLE) of a phase III study

Abstract

Long-term efficacy and safety adalimumab in children with juvenile rheumatoid arthritis (JRA): converting from body-surface-area dosing to weight-based fixed dosing in the open-label extension (OLE) of a phase III study